A new standard in cancer care: Integrated screening, stepped collaborative care for common and distressing symptoms

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.

November 15, 2024

Vol.50 No.43

Clinical Trials & Tribulations

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more

Long-term risks from prostate cancer treatment detailed in new report

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

November 08, 2024

Vol.50 No.42

In Brief

UF Health Cancer Center rolls out mobile cancer screening vehicle

UF Health officials and supporters gathered Wednesday to unveil the UF Health Cancer Center’s Mobile Cancer Screening Connector, which will take cancer screening care to a 23-county area in North Florida. UF Health photo by Nate GuidryThe University of Florida Health Cancer Center launched a 40-foot-long mobile cancer screening bus that will expand access to cancer screenings and essential health care services, including 3D mammograms and cervical, colon, and prostate cancer screenings.

November 01, 2024

Vol.50 No.41

Clinical

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center were awarded a $3 million grant from NIH to improve follow-up care for colorectal cancer screening in underserved populations.

October 04, 2024

Vol.50 No.37

A new standard in cancer care: Integrated screening, stepped collaborative care for common and distressing symptoms

YOU MAY BE INTERESTED IN

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

UF Health Cancer Center rolls out mobile cancer screening vehicle

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Renew today!

Subscriber content

Never miss an issue!

Login

A new standard in cancer care: Integrated screening, stepped collaborative care for common and distressing symptoms

YOU MAY BE INTERESTED IN

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

UF Health Cancer Center rolls out mobile cancer screening vehicle

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Never miss an issue!

Login

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment